Table 1.
Patient’s characteristics
| Clinical variables | Median (range) |
|---|---|
| Age at first cycle of PSMA RLT (years) | 71 (46–88) |
| IntervalDiagnosis-RLT (months) | 62 (9–274) |
| Treatment cycles per patient | 3 (1–8) |
| Cumulative activity (GBq) | 14.4 (4.8–50.9) |
| Gleason score | 9 (6–10) |
| Baseline laboratory values | |
| PSA (ng/ml) | 159 (2.9–3590) |
| CRP (mg/dl) | 0.75 (0.01–29.3) |
| LDH (U/l) | 268.5 (152–1800) |
| Hemoglobin (g/dl) | 11.8 (6.0–14.8) |
| AST (U/l) | 29.0 (13.8–546.7) |
| AP (U/l) | 146.0 (31.0–5818) |
| Baseline PET parameters | |
| PSMA-TV (cm3) | 546.7 (7.9–3820) |
| TL-PSMA (cm3) | 4998 (51.7–32,065) |
| SUVmax | 63.4 (13.2–424.5) |
| SUVpeak | 33.3 (8.5–181.6) |
| SUVmean | 9.4 (4.3–23.7) |
| Sites of metastases | n (%) |
| Bone | 101 (98.1) |
| Lymph node | 71 (68.9) |
| Visceral | 38 (36.9) |
| Liver | 22 (21.4) |
| Lung | 14 (13.6) |
| Prior treatments | % |
| Radical prostatectomy | 40.8 |
| Primary radiation therapy to the prostate | 11.7 |
| Antihormonal treatment | 100 |
| Enzalutamide | 70.9 |
| Abiraterone | 70.9 |
| Chemotherapy | 77.7 |